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Investigating histidinylated highly branched
poly(lysine) for siRNA delivery
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Ruman Rahman, c Keith Spriggsb and Cameron Alexander *b
The temporary silencing of disease-associated genes utilising short interfering RNA (siRNA) is a potent
and selective route for addressing a wide range of life limiting disorders. However, the few clinically
approved siRNA therapies rely on lipid based formulations, which although potent, provide limited
chemical space to tune the stability, efficacy and tissue selectivity. In this study, we investigated the role
of molar mass and histidinylation for poly(lysine) based non-viral vectors, synthesised through a fully
aqueous thermal condensation polymerisation. Formulation and in vitro studies revealed that higher
molar mass derivatives yielded smaller polyplexes attributed to a greater affinity for siRNA at lower N/P
ratios yielding greater transfection efficiency, albeit with some cytotoxicity. Histidinylation had a
negligible effect on formulation size, yet imparted a moderate improvement in biocompatibility, but did
not provide any meaningful improvement over silencing efficiency compared to non-histidinylated
derivatives. This was attributed to a greater degree of cellular internalisation for non-histidinylated
analogues, which was enhanced with the higher molar mass material.
Introduction
RNA interference (RNAi) is an evolutionarily conserved pathway
that enables post-transcriptional regulation of gene expression
through cleavage and degradation of messenger RNA (mRNA)
in a selective manner. This is accomplished by utilizing short
(21–25 base pair) double-stranded non-coding RNA (dsRNA),
such as siRNA (small interfering RNA) to transiently interfere
with mRNA translation.1–4 In principle it is possible to target
specifically any transcribed genes providing its sequence is
known, therefore RNAi has attracted attention as a potent
and selective therapeutic approach for a range of diseases
particularly cancers, and those lacking ‘druggable’ targets,5 by
downregulating expression of disease related proteins.
However, the bioavailability of administered ‘naked’ siRNAs
at their intracellular target, the cytosol, is limited by, instability
against endogenous nucleases, poor cellular uptake and weak
endosomal escape.6–9 Therefore, several non-viral delivery
systems, including polymeric nanoparticles and liposomes
have gained attention as synthetic carriers for genetic material,
including siRNA, in order to overcome the limitations of
unpackaged nucleic acids, and thus to enhance cell specificity
and knockdown efficiency.4
Polymeric delivery systems are typically designed around
cationic moieties which can electrostatically condense
negatively charged nucleic acids into small (o200 nm diameter)
polyelectrolyte complexes, often referred to as polyplexes.10–13 In
contrast to other formulation systems, the chemical versatility
that can be derived for polymeric materials, for example through
variations in molar mass,14 architecture,15 and monomer
chemistries16 offers significant adaptability to tune physical
properties including stimuli responsiveness,17 particle size, sur-
face charge, and therapeutic loading capacity.18 In turn, these
factors enable modulation of biological activities, such as
biodistribution,19 cytocompatibility, cellular uptake20 and endo-
somal escape,21 allowing macromolecular gene delivery vectors
to target specific tissue types or diseases. Of the many polymer–
gene delivery systems reported, branched macromolecules have
garnered significant attention due to their dense and globular
architecture, larger surface area compared to linear polymers
and controllable charge density which have been reported to
enhance nucleic acid condensation and transfection
efficiency.22,23 These properties are most evident from the wide-
spread use of the branched polycation, poly(ethyleneimine),
bPEI, which has demonstrated higher transfection efficiency
over the linear analogue albeit with significant cytotoxicity
concerns under certain biological settings.24 Nonetheless, this
architectural blueprint has paved the way for an array of highly
effective branched polycations derived from numerous material
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platforms, such as poly(b-aminoester)s,23 poly(amidoamine)s,25
poly(amino acids)/polypeptides,26 partially hydrolysed
poly(oxazoline)s27 and poly(meth)acrylates/acrylamides.28
Although many of these delivery platforms offer high
potency, future clinical use also depends on their scalability
and straightforward manufacture, which ideally should occur
under aqueous conditions to avoid potential toxicity from
organic solvents, catalysts and side products. We and others have
reported on the use of an aqueous atom-economical ‘one-pot’
thermal condensation polymerisation to prepare highly branched
poly(lysine) (hb-polyK) and poly(lysine-co-histidine) (hb-polyKH2)
utilising the ABB’ structure of lysine for branching.26,29–34 This
approach offers a practical route to biodegradable cationic
poly(amino acid)s, which in our previous studies exhibited high
transfection efficiency for plasmid DNA cargo but have not yet
been explored as siRNA vectors.26
Accordingly, in this work we investigate the activity of both
hb-polyK and histidinylated hb-polyK to condense and deliver
siRNA. To this end, the two different molecular mass variants of
hb-polyK (13 and 33 kDa) and histidinylated hb-polyK (18 and
34 kDa); denoted by hb-polyK-13 kDa, hb-polyK-33 kDa, hb-
polyKH2-18 kDa and hb-polykH2-34 kDa respectively, were used
to condense siRNA and the resultant polyplexes were evaluated
for their physico-chemical properties and biological function.
Materials and methods
Materials
Polymers hb-polyK-13 kDa, hb-polyK-33 kDa, hb-polyKH2-18 kDa,
hb-polykH2-34 kDa copolymers and their labelled forms were
synthesised and characterised as reported in our previous
work.29 Luc-siRNA (target sequence: 50-CCGCAAGAUCCGCGA-
GAUU-30) and negative control (scrambled) siRNA were purchased
from Eurogentec (Seraing, Liège, Belgium). Silencert Select
GAPDH Positive Control siRNA and Cy3 labelled siRNA was
obtained from Thermo Fisher Scientific (Loughborough, UK).
GAPDH activity assay kits were received from Source Bioscience
(Nottingham, UK), and RNase free water from Sigma-Aldrich
(Gillingham, UK) The Luciferase assay kits were from Promega
(Madison, WI, USA). All cell culture products including Dulbecco’s
modified Eagle’s medium (DMEM), Roswell Park Memorial
Institute media RPMI), foetal bovine serum (FBS), phosphate-
buffered saline (PBS), L-glutamic acids were obtained from Sigma-
Aldrich (Gillingham, UK). All the other materials were obtained
from Sigma-Aldrich (Gillingham, UK) and used without further
purification unless stated.
Preparation of polyplexes
The siRNA polyplexes derived from hb-polyK-13 kDa, hb-polyK-
33 kDa, hb-polyKH2-18 kDa and hb-polykH2-34 kDa were
prepared at 40 mg ml1 siRNA in HEPES buffer (10 mM in
RNase free water, pH 7.4). The concentrations of the polymers
were adjusted to be equivalent to the required nitrogen/
phosphate (N/P) ratio. Polyplexes were formulated by mixing
equal volumes of siRNA and the polymer solutions, vortexed for
10 s, and incubated for 30 min at room temperature before
further use.
Particle sizes and zeta potential measurements
The hydrodynamic radii of siRNA polyplexes were measured
using a Viscotek 802 instrument supported by Omnisize 0.3 V
software, where all the measurements were carried out at a
scattering angle of 901 and a temperature of 25 1C and the
results were recorded as average of 10 runs  SD. For zeta
potential, the prepared polyplexes were diluted to using a
solution of 5 mM NaCl (1 ml) and the measurements were
performed using a NanoZetasizer (Malvern, UK) and recorded
as three readings of 10–20 runs each.
Atomic force microscopy
Polymer/siRNA polyplexes prepared at N/P ratio of 10 in HEPES
buffer (10 mM, pH 7.4) were examined by Atomic Force Micro-
scope (AFM) imaging using Mica as a support disc. The specimens
were prepared by depositing 100 ml of polyplexes (40 mg ml1 of
siRNA) on freshly cleaved Mica for 30 s, and then the excess of
solution was removed. Samples were dried using dry filtered air
for 1 min before being imaged in air using the Peak Force Tapping
mode of Fast Scan AFM (Dimension ICON from Bruker). The
cantilevers were Tap150A with a spring constant of 5 N m1
operating at resonant frequencies of approximately 150 kHz.
Images were analysed using Nanoscope Software version 7.3.
Gel retardation assays (agarose gel electrophoresis)
The hb-polyK polymers were dissolved in HEPES buffer
(10 mM, pH 7.4) and mixed with 0.5 mg siRNA at various N/P
ratios. After incubating for 30 min at room temperature, the
obtained sample, the mixture of the 6-loading dye (5 ml) and
siRNA polyplexes (25 ml), were loaded onto 1% (w/v) agarose gel
that was prepared with 1% Tris–acetate–EDTA buffer solution
and contains 2 mg ml1 ethidium bromide. Electrophoresis was
performed at 70 V for 60 min, after which the gel was imaged
using a UV-transilluminator (Syngene, Germany).
Ethidium bromide displacement assay
Ethidium bromide displacement was measured using a
Tecan Microplate reader (Sparks). The test siRNA solution
(40 mg ml1 in HEPES, 10 mM, pH 7.4) was incubated with ethidium
bromide (2 mg ml1) for 15 minutes. Next, aliquots of 50 ml were
mixed with 50 ml of polymer solutions at concentrations equivalent
to the different N/P ratios. The samples (n = 4) were incubated for
30 minutes at the room temperature, and then the fluorescence
intensity of siRNA–ethidium bromide intercalate was measured at a
wavelength of 590 nm using an excitation wavelength of 520 nm.
Cell culture
A549 (human adenocarcinoma alveolar basal epithelial, ATCCs
CCL-185) cells stably expressing the firefly luciferase transgene
denoted by Luc-A549, and H1299 (human non-small cell lung
carcinoma, ATCC CRL-5803) were cultured in DMEM and RPMI,
respectively, supplemented with 10% FBS and 1% L-glutamic
acids under a humidified atmosphere containing 5% CO2.
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Routinely, the cells were cultured in a T75 flask and split when
approximately 90% confluent using Trypsin/EDTA to detach
the cells.
Toxicity assays
The effects of siRNA polyplexes on target cell lines (Luc-A549 or
H1299) were determined with two different methods; membrane
leakage via the lactate dehydrogenase (LDH assay), and mito-
chondrial function (MTT assay). Both assays were performed by
following the manufacturer’s instructions. In brief, Luc-A549 or
H1299 cells were seeded on 96-well plates at density of
25 000 cells per well in 100 ml of culture medium for 24 hours.
Subsequently, the culture media were replaced with the trans-
fection medium (FBS free medium) containing siRNA polyplexes
at different N/P ratios (final concentration of siRNA was
2 mg ml1 in FBS-free media) and incubated for 4 hours.
Thereafter, the treatment medium was collected for conducting
LDH assays, replaced with fully supplemented medium, and the
cells were incubated for a further 24 hours for the MTT assay.
Lactate dehydrogenase (LDH) detection assay
At 4 h post-transfection, 50 ml aliquots of the treatment medium
were mixed with 50 ml LDH reagent and the contents were kept
at room temperature for 20–30 min before adding the stop
solution (5 ml). The released LDH was detected by measuring
the absorbance at 490 nm using a Tecan Microplate reader. The
cells treated with Triton (0.2% in HEPES) and FBS free medium
were used as controls and the percentage of released LDH was
calculated using the following equation:
Released LDH (%) = S  C/T  C  100
where, S is the absorbance obtained with the tested samples, T
is the absorbance observed with Triton used as positive control,
and C is the absorbance observed with the FBS free media
treated cells utilised as negative control.
Metabolic activity (MTT) assay
To determine metabolic activity, after the 24 h post-transfection
incubation, 25 ml of MTT reagent (5 mg ml1 in PBS) was added
to each well and the cells were incubated for 3 hours. DMSO
(150 ml) was then added and mixed thoroughly before measuring
the absorbance at 570 nm using a Tecan Microplate reader.
The untreated cells and cells treated with Triton 0.2% were used
as negative and positive controls. The metabolic activity of
negative control was accepted as 100% whilst that of positive
control 0%, and the percentage of metabolic activity of
specimens was calculated using the following equation:
Metabolic activity (%) = S  T/C  T  100
where, S is the absorbance obtained with the tested samples,
T is the absorbance observed with Triton, and C is the absor-
bance observed with the untreated cells.
In vitro transfection study
The cells, LucA459 or H1299, were seeded into a 24-well plate at
a density of 5  104 cell per well and incubated in 500 ml of fully
supplemented medium, 24 h before transfection. Then, the cells
were washed with PBS, covered with 500 ml of FBS free medium
and treated with Luc-siRNA and GAPDH-siRNA polyplexes for
Luc-A549 and H1299 cells respectively (at a concentration of 1 mg
of siRNA per well). After 4 hours, the transfection medium was
replaced with fully supplemented medium, and the cells were
incubated for further 24 hours. Then, the cells were washed with
PBS and lysed in reporter lysis buffer (Promega), 100 ml for each
well. Luc-A549 lysate was used to detect the expression of
luciferase using luciferase assay kit (Promega) and H1299 lysate
to detect the expression of GAPDH using GAPDH activity assay
kit (Source Bioscience), following the supplier’s protocol.
The results were normalised using total protein concentration
of each sample, which was detected using a Coomassie Plus
(Bradford) assay kit (following the supplier’s protocol).
Cellular uptake
Polyplexes were prepared using FITC-labelled polymers and Cy3
labelled siRNA. For confocal microscopy, the cells (Luc-A549 or
H1299) were seeded into 8-well chamber slides (from Ibidi) at a
seeding density of 20 000 in 300 ml fully supplemented growth
medium. After 24 hours, the cells washed with PBS, covered
with 300 ml of FBS free medium, and treated with the labelled
siRNA polyplexes at concentration of 2 mg of siRNA per ml for 4
hours. Then, the cells were washed with PBS three times, fixed
with 4% paraformaldehyde for 15 minutes, stained with DRAQ5
(20 mM in PBS for 5 minutes) or Hoechst (1 mg ml1 in PBS for
10 minutes), and then covered with mounting medium.
The samples were imaged using a Zeiss 510 Meta Confocal
microscope. For flow cytometry, after the incubation of cells
with labelled siRNA polyplexes for 4 hours, the cells were
washed with PBS three times, and then detached from the
plates using 500 ml of AccutaseTM solution for 15 minutes at
37 1C. The cells were collected in FACS tubes, mixed with 150 ml
of Trypan blue (4%) and measured directly using a Beckman
Coulter Astiros flow cytometer and data were analysed using
Kaluza 1.5 software.
Statistical analysis
All experiments in the study were performed at least three times
as independently and the data are expressed as mean  SD
or SE (standard deviations or standard error, respectively). Statis-
tical analyses of the results were evaluated by using One-way or
Two-way ANOVA with a Tukey’s multiple comparison based on
the number of variables on graphs. Where * = significant (p o
0.05), ** = very significant (p o 0.01), *** = extremely significant
(p o 0.001), and **** = extremely significant (p o 0.0001).
GraphPad Prism 9.0 software was used for data analysis.
Results
Variations of polyplex size and siRNA condensation with molar
mass and histidinylation
In this study, we utilised four previously prepared highly branched
lysine or lysine-co-histidine poly(amino acids) (hb-polyK-13 kDa,
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hb-polyK-33 kDa, hb-polyKH2-18 kDa and hb-polyKH2-34 kDa)
synthesised at a low (B13–18 kg mol1) or high molar mass
(B35 kg mol1) in order to evaluate the impact of molar mass
and histidinylation on siRNA complexation and transfection
efficiency. Polyplexes were prepared by mixing polymer and siRNA
components at various N/P ratios, with nitrogen content
calculated based on a fluorescamine assay performed in our
previous study.29 The properties of these polymers are given in
Table 1 and their structures and representation of polyplexes
formed with siRNA are given in Scheme 1.
Initial evaluation of the formulations revealed stronger
siRNA binding capacity for the non-histidinylated
polymers, as evidenced by the maximum fluorescence
reduction and full siRNA complexation being achieved at
lower N/P ratios compared to the histidinylated polymers in
the ethidium bromide displacement assay (Fig. 1A). In
addition, the gel retardation data (Fig. 1B), suggested that
the lysine-only polymers were better at retaining siRNA, and
with the higher molar mass hb-polyK retarding siRNA fully at
N : P 2.
Table 1 Properties of thermally polymerised hyperbranched polymers29
Polymer K : H ratioa Mn
b (kDa) Mw
b (kDa) (Ð) DBc ANBd Buffer capacitye mmol of aminef
hb-polyK-13 kDa — 13.4 22.7 1.7 0.34 0.24 35.2% 5.3
hb-polyK-33 kDa — 33.6 58.8 1.7 0.39 0.27 37.4% 5.3
hb-polyKH2-18 kDa 10 : 2 18.1 25.3 1.4 0.46 0.39 44.0% 4.0
hb-polyKH2-34 kDa 10 : 2 34.5 62.8 1.8 0.40 0.32 43.9% 3.6
a Molar ratios of lysine to histidine. b Malls GPC molecular masses. c Degree of branching. d Average number of branches. e Buffer capacity at pH
range of 5–7. f mmol of amine per mg of polymers (fluorescamine assay).
Scheme 1 Representative structures of hyperbranched poly(lysine) and poly(lysine-co-histidine) and complexes with siRNA.
Fig. 1 (A) Ethidium bromide displacement assay of siRNA polyplexes prepared in 10 mM HEPES (pH 7.4) at different N/P ratios. (B) Agarose gel
electrophoresis of hyperbranched polymers/siRNA polyplexes prepared in 10 mM HEPES, pH 7.4 at N/P 1–20. siRNA and polymer lanes represent the free
siRNA (0.5 mg) and free polymer (amount equivalent to that of N/P ratio of 20) respectively.
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Interestingly, although full siRNA complexation was
achieved at lower N/P ratios for the higher molar mass polymers
across both compositions, the same trend was not evident in the
ethidium bromide displacement study. The importance of
‘matching’ charge distribution in polyelectrolyte interactions is
reported in several studies,35–37 where ‘mismatching’ the
charge between two opposite electrolytes leads to swollen and
incompletely compacted complexes.
Particle sizes of polyplexes derived from all four branched
polymers displayed an N/P ratio dependent trend, with hydro-
dynamic radii decreasing with increasing polymer concentra-
tions (N/P ratio), culminating in all polymers condensing siRNA
sufficiently at N/P = 20 to produce sub-200 nm radii particles
(Fig. 2A). The inversion of zeta potential measurements from
positive to negative occurred at BN/P = 2 for all polyplexes, with
the minimum zeta potential (B15 mV) recorded at N/P = 0.5
which increased with N/P ratio, reaching a maximum at N/P =
20 (B12 mV) (Fig. 2B).
This steady increase in zeta potential with N/P ratio likely
contributes a greater electrostatic stabilisation of these complexes,
evidenced by their smaller particle size. Zeta potentials of
polyplexes derived from the high molar mass polymers were
generally higher than that of their low molecular analogue, but
no discernible difference was seen in the zeta potentials due to
Fig. 2 The characterisation of siRNA polyplexes with hb-polyK-13 kDa, hb-polyK-33 kDa, hb-polyKH2-18 kDa, hb-polyKH2-34 kDa that form at various
N/P ration in HEPES (10 mM, pH 7.4 buffer by using DLS and AFM (A) hydrodynamic radii of siRNA polyplexes, (B) the zeta potential measurements of the
polyplexes. The results are shown as mean and SE values of three independent experiments (using 10 sub-runs and 3 runs for each hydrodynamic
radii and zeta potential experiments respectively by utilizing DLS). (C) Atomic force micrographs show the siRNA polyplexes of hb-polyK-33 kDa and
hb-polyKH2-34 kDa at N/P ratio of 10. The images were analysed using particle size analysis function of ImageJ software (version 2.0.0-rc-59/1.51j) and
the obtained histograms show the size distribution of polyplexes.
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histidinylation. Although the electrostatic interactions are the
main determining forces in polycation:nucleic acid complexes,
some studies have shown that non-ionic interactions such as
hydrogen bonds and hydrophobic interaction contribute signifi-
cantly to these complexes.38–40 In the case of siRNA, the presence
of the 20 hydroxyl group of ribose provides potential hydrogen
bond acceptors,41 which could explain the relative stability of
siRNA polyplexes with nearly neutral zeta potentials.
Particle size and morphology were further validated through
AFM measurements for polyplexes derived from all four poly-
mers at N/P = 10 (Fig. 2C). Atomic force micrographs indicated
that the polymers could compact the siRNA into small spherical
nanoparticles with a relatively broad size distribution; the
polyplex diameters varied between 40–200 nm. The smaller
average size of siRNA polyplexes reported by AFM compared to
DLS is attributed to the deposition and drying of polyplexes
onto the Mica substrate compared to hydrated complexes
under light scattering measurements. Furthermore, micro-
scopy analyses show more clearly the number distributions of
polyplexes, while the intensity DLS histograms are skewed
towards larger particles. Overall, our formulation studies
indicate that all four polymers display efficient siRNA binding
and form relatively small (o200 nm radii polyplexes).
Evaluation of membrane damage and changes in metabolic
activity in cells treated with polymer:siRNA complexes
Polycations are known to disrupt cell membranes and induce
toxicity. Accordingly, the effects of the complexes on cell mem-
branes and metabolic activity were evaluated by monitoring lactate
dehydrogenase release (LDH) and MTT conversion in two cell
lines of importance in lung cancers, i.e. Luc-A549 and H1299
cells, treated with siRNA complexes derived from the four
branched polycations and branched 25 kDa PEI as a control,
all formulated with 2 mg ml1 siRNA at N/P ratios 10 to 100.14
To evaluate any acute cell membrane disruption, LDH
release was monitored after the initial 4 hours’ exposure to
the siRNA polyplexes (i.e., before polyplex removal and serum
supplementation). In Luc-A549 cells, none of the branched
polyplexes showed a severe negative influence on plasma
membrane integrity at up to N/P ratio of 80, indicated by
o20% LDH release, meanwhile PEI polyplexes displayed
significantly higher (30–40%) LDH release at N/P ratio 410.
In contrast, hb-polyK-13 kDa, hb-polyK-33 kDa, and
hb-polyKH2-34 kDa polyplexes induced an increasing LDH
release profile with higher N/P ratios in H1299 cells, comparable
to that of PEI polyplexes (35% at N/P = 20). The polyplexes of
hb-polyKH2-18 kDa showed the least impact on the integrity of
H1299 membrane with negligible LDH release at N/P ratios of up
to 80 (Fig. 3A). Overall, the membranes of H1299 cells were more
sensitive to polyplex treatments than Luc-A549 cells, possibly
attributed to differences in fluidity and composition between
A549 and H1299 cell membranes. For instance, A549 cells
produce large amounts of lecithin, which is a major contributor
to phospholipid biosynthesis, thus may provide greater structural
integrity in comparison with H1299.26,42,43 Interestingly, the most
membrane active polyplexes displayed a plateau in LDH release
at high N/P ratios, suggesting the interaction of those polyplexes
(or the associated non-complex polycation) reached a maximum
Fig. 3 (A) Relative LDH release and (B) relative metabolic activity of Luc-A549 and H1299 cells treated with siRNA polyplexes of hb-polyK-13 kDa,
hb-polyK-33 kDa, hb-polyKH2-18 kDa, hb-polyKH2-34 kDa and PEI at different N/P ratios. The cytotoxic effects of siRNA complexes formed from the
hyperbranched polymers and PEI represent the average of the four independent experiments performed in triplicate.
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at N : P B 40, which may have been indicative of binding
saturation at intracellular membranes.
To examine cytotoxicity, metabolic activity of the cells was
assessed by an MTT assay 24 h post-transfection (Fig. 3B).
In both cell lines the metabolic activity decreased with
increased N/P ratios across all siRNA polyplex formulations;
however this trend was not identical across the cell lines and
was more pronounced in H1299 cells than A549 cells. In
addition, H1299 cells displayed significantly lower metabolic
activity when treated with polyplexes from all polymers except
hb-polyKH2-34 kDa over N/P = 20 compared to A549 cells,
with metabolic activities below 40% recorded for the non-
histidinylated derivatives in this cell line, compared to that of
PEI. The difference between A549 and H1299 may be attributed
to the differences in membrane fluidity as reported
previously.26,42,43 No substantial differences in metabolic activity
were observed in cells treated with the high molecular weight
polymers.
High molar mass derivatives display most pronounced gene
silencing, with histidinylation negatively affecting knockdown
efficiency
To assess the in vitro siRNA transfection efficiency of the
hyperbranched polymers, the expression of Luciferase (firefly)
and GAPDH genes was knocked down in Luc-A549 and H1299
cells using polyplexes prepared at N/P ratios of 5, 10 and 20.
The knockdown efficiency was evaluated as a percentage relative
to enzyme/protein activity in cells treated with polyplexes
containing scrambled siRNA (Fig. 4).
The most pronounced silencing in Luc-A549 cells was
observed with polyplexes derived from the polymers with high
molar mass (hb-polyK-33 kDa and hb-polyKH2-34 kDa), with
the lysine-only analogue most effective at all N/P ratios (70%,
50% and 70%, 60% silencing for N/P = 10 and 20 respectively).
Notably, the higher molar mass histidinylated derivative
(hb-polyKH2-34 kDa) displayed marginally lower knockdown of
luciferase expression than non-histidinylated analogues,
suggesting minimal silencing improvement from histidinylation
(25, 50 and 60% knockdown at N/P rations 5, 10 and 20
respectively). Polyplexes from the low molar mass polymers
(hb-polyK-13 kDa and hb-polyKH2-18 kDa) did not show a
statistically significant silencing effect on luciferase expression
(Fig. 4A).
In H1299 cells, a similar trend of gene silencing was
observed, where only the polyplexes of hb-polyK-33 kDa and
hb-polyKH2-34 kDa achieved a significant reduction in GAPDH
activity (35% and 25% at N/P of 10 and 20 respectively).
Interestingly, the overall silencing efficiency was lower in
H1299 cells compared to Luc-A549 across all treatments,
including PEI, suggesting that this was either due to the
efficiency of siRNA itself in recognition or availability to GAPDH
encoding mRNA, or is cell dependent (Fig. 4B). According to
these in vitro transfection results, siRNA delivered by polyplexes
derived from the higher molar mass polymers (hb-polyK-33 kDa
and hb-polyKH2-34 kDa) induced superior gene knockdown
than lower molar mass derivatives, a structure–function trend
which has been reported in many other studies.14,32
Flow cytometry and confocal microscopy analysis of polyplex
internalisation in A549 and H1299 cells
To gain a greater insight into the silencing properties of the
siRNA polyplexes and to probe potential mechanisms for the
variations in knockdown efficiency, the internalisation of
the polyplexes in A549 and H1299 cells was studied using Cy3-
labelled siRNA and FITC-labelled polymers. The Cy3 signal
(siRNA) from flow cytometry analysis of both cell lines treated
with fluorescent polyplexes indicated the highest internalisation
occurred with PEI, followed by hb-polyK-33 kDa across all
tested N/P ratios, with all other complexes displaying low
Fig. 4 (A) Luciferase activity in Luc-A549 cells and (B) GAPDH activity in
H1299 cells transfected with siRNA polyplexes of hb-polyK-13 kDa, hb-
polyK-33 kDa, hb-polyKH2-18 kDa, hb-polyKH2-34 kDa and PEI (N/P =
10) at a concentration of 2 mg ml1 of siRNA. The results were normalised
using total protein measurements and presented as percentages of the
controls (expression of the cells transfected with scrambled siRNA using
N/P ratio of 10 of different polymers). The silencing ratio represents the
average of four independent experiments performed in triplicate. Statis-
tical analysis of the comparison knockdown efficiency based on the
corresponding control lines was performed by using a two-way ANOVA
test followed by a Tukey’s multiple comparison test, where *p o 0.05,
**p o 0.01, ***p o 0.001, and ****p o 0.0001.
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internalisation of the labelled siRNA (Fig. 5A, B and C, D).
The increased relative cellular uptake of PEI and hb-polyK-33
kDa is likely a major contributor to the enhanced knockdown
efficiencies observed above. Comparatively, the FITC signal
(polymers) did not show an identical trend to the Cy3 signal,
suggesting large proportions of free polymer not associated with
the polyplex were also associating with the cell membranes or
being internalised, particularly in the case of lysine-only analogues.
Confocal micrographs of hb-polyK-33 kDa (lysine-only) and
hb-polyKH2-34 kDa (histidine containing) displayed punctate
Cy3 signal indicating polyplexes were likely internalised through
endosomal uptake in both cell lines (Fig. 6). Interestingly, the
images showed that there was poor colocalization between the
signals of Cy3-labelled siRNA (red channel) and FITC-labelled
polymers (green channel), suggesting a dissociation of
polyplexes and release of the siRNA at the time of imaging
(after 4 hours of treatment), or as suggested above, uptake of
polymers not associated with the polyplexes. Similarly, in H1299
cells, polyplexes derived from high molar mass polymers were
internalised significantly (2-fold) more than lower molar mass
analogues based on the Cy3 (siRNA) median intensity (Fig. 6B)
The FITC signal (polymer) again did not show the same fluores-
cence trend as the Cy3 (siRNA) signal, indicating uptake of
uncomplexed polymer. It should be noted that fluorescein dyes
are pH sensitive and their fluorescence can be quenched in the
acidic environment of late lysosomes. Thus there may have been
an underestimate of the amount of complexed polymer in these
intracellular compartments. However, the inherent buffering by
the polymers within the complexes and thus the modulation of
local pH renders a full interpretation of polymer content in the
endo/lysosomes difficult. Nevertheless, when taken together, the
results indicated that the hyperbranched polymers of higher
molar masses were able to deliver siRNA more efficiently than
the lower molecular mass polymers and that histidinylation did
not have a positive effect on transfection efficiency or cellular
uptake.
Discussion
When the results are evaluated together, it is clear that the high
molar mass analogues exhibit the highest transfection efficiencies
and cellular uptake, likely arising from a greater propensity to
condense siRNA into smaller, and more colloidally stable
polyplexes with positive zeta potentials at lower N/P ratios. This
is in agreement with data reported in the literature, where higher
molar mass polymers are required to condense the relatively small
siRNA nucleic acids into stable polyplexes, which have low charge
and high rigidity of siRNA relative to plasmid DNA or mRNA.8,44,45
Interestingly, these results are in contrast to our previously
reported findings for plasmid DNA polyplexes with these
polymers, where low transfection efficiency was obtained
with the polyplexes of the higher molecular mass polymers.29
This we attributed primarily to the formation of highly stable
Fig. 5 Flow cytometry results of uptake study in (A and B) Luc-A549 cells and (C and D) H1299 cells using Cy3-labelled siRNA and FITC-labelled
polymers. The results are shown as median of fluorescence intensity, where the data represent mean and SD values (n = 2), Statistical analysis was
performed by using a two-way ANOVA test followed by a Tukey’s multiple comparison test, where *p o 0.05, **p o 0.01, ***p o 0.001, and ****p o
0.0001.
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polyplexes, with poor unpacking to release their payload, and
the fact that access of DNA to the nucleus is needed for effective
mRNA and subsequent protein production. Accordingly, there
is a fine balance between stable complexation and intracellular
decomplexation, and has previously been noted to be very
important for efficient transfection.46,47 Thus, the variations
between plasmid DNA and siRNA in size and flexibility gave an
advantage for the higher molecular mass polymers, in the case
of siRNA, to form relatively stable polyplexes with good intra-
cellular decomposition and siRNA release, as suggested by
confocal images (which showed poor colocalisation between
the signals of siRNA and the polymers). Similarly, Kwok et al.48
compared complexation of linear and branched PEI with both
siRNA and DNA and correlated the results of transfection with
the stability of the polyplexes in the presence of heparin. They
found that the transfection of the more stable polyplexes of
branched PEI was better than that for the polyplexes of the
linear PEI in the case of siRNA. However, linear PEI, which
showed better unpacking properties, achieved better transfection
in the case of DNA polyplexes. Zhou et al.49 found that the gene
silencing of polyamidoamine dendrimers was a function of the
dendrimer generation, where the high generations produced
more stable complexes. Also, it was reported that the improved
stability of siRNA polyplexes provided with cysteine, which act as
an inner crosslinker (using disulfide linkages), enhanced the
transfection of those polyplexes significantly.
Furthermore, our results revealed that the lysine-only
polymer (hb-polyK-33 kDa) has a better silencing efficiency in
comparison with the histidine-containing polymer (hb-polyKH2-
34 kDa). This could be explained by the effect of histidine on the
structure of the polymer; the incorporation of histidine (an AB
type monomer) during thermal polycondensation produced
polymers of more dendritic units through the ‘capping’ of
partially reacted lysine monomers, thus restricting the flexibility
of these analogues.29 This, in combination with the small size
and stiffness of siRNA, would affect the condensing ability of the
histidinylated polymers, as shown clearly in ethidium bromide
displacement and gel retardation. Also, the incorporation of
histidine might affect the ability of the polymers to interact
with, and permeabilise, the cellular membrane, particularly for
the low molecular mass polymers, as indicated by LDH assays.
All these factors, in turn, affected the cellular uptake and
silencing efficiency of the polyplexes of the histidinylated
polymers.
The weaker membrane interaction of the histidinylated
polymers could also be expected to affect their ability to escape
from the endosomal barrier. In this regard, the uptake study
revealed (based on the signal of FITC-labelled polymers) that
the histidinylated polymers, free or associated with polyplexes,
accumulated to less extent inside the cells than the lysine-only
polymers. This supports the assertion that endosomal escape
might be affected in the case of histidinylated polyplexes, where
the effect of free polymer on endosomal buffering was well
reported.50,51
Conclusion
In this study we investigated the ability of highly branched
poly(lysine) and poly(lysine-co-histidine) polycations to condense
and deliver siRNA for potential gene silencing therapies.
Fig. 6 Confocal images show the uptake of hb-polyK-33 and histidine containing hb-polyKH2-34 kDa complexes with siRNA in Luc-A549 and H1299 cells,
where areas in green are FITC-labelled polymers, area in red are Cy3-labelled siRNA, regions in yellow are assigned to overlaid Cy3-labelled siRNA and FITC-
labelled polymers, areas in blue correspond to Hoechst stained nuclei of A549 cells, and areas in purple correspond to DRAQ5 stained nuclei of H1299 cells.
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The physicochemical characterization indicated that the
polymers of higher molar masses yielded smaller polyplexes
with higher zeta potentials at lower N/P ratios than lower molar
mass analogues, suggesting a greater affinity for siRNA.
Consequently, higher molar mass polymers exhibited a higher
degree of cellular uptake, leading to more potent silencing
efficiency without significant cytotoxicity at N/P ratios where
silencing was effective. This was likely due to the small size of
these nucleic acids, imparting low overall charge and rigidity,
which required polycations of relatively high molecular mass to
condense them into stable nanoparticles. While there is always
the caveat with hyperbranched polymers that polydisperse
samples, for which in our case the Ð values ranged between
1.4–1.8, these findings provide important structure–property
relationships for future designs of polymeric non-viral vectors
for siRNA. Furthermore, the data highlight the necessity to
design vectors for specific nucleic acid cargoes which retain
vital features such as biodegradability, cytocompatibility, and
manufacturability for further clinical assessment.
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